O-022 - Outcomes based on Albumin‐Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
| Autor: | Miksad, R., Cicin, I., Chen, Y., Klumpen, H., Kim, S., Lin, Z., Youkstetter, J., Sen, S., Cheng, A., Meyer, T., Kelley, R., Abou-Alfa, G. |
|---|---|
| Zdroj: | In Annals of Oncology July 2019 30 Supplement 4:iv134-iv134 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|